CMG Pharma

본문내용 바로가기
헤더 바로가기
푸터 바로가기

Pangyo Headquarters: 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Cha Hospital Group Pangyo Comprehensive Research Institute

Sihwa Factory: 27 Gongdan 1-daero 27beon-gil, Siheung-si, Gyeonggi-do

TEL : 031-881-7600
FAX : 031-881-7670

Driving change through innovation, performance, and ethical collaboration

Innovating for healthier lives

Growing beyond Korea into a global pharmaceutical company

Healthcare Solutions

CMG Pharma is building an integrated healthcare portfolio that encompasses
prescription and over-the-counter drugs, as well as dietary supplements,
pet healthcare, and medical devices. With the use of the healthcare portfolio, we provide
value optimized for customers and the market through various channel strategies, including B2C and B2B.

Prescription Drugs

Over-the-Counter Drugs

Dietary supplements

Medical Devices

Pet Business

Supplements / Treats / Supplies

R&D Platform

CMG pharma is continuously developing platform formulation technologies,
enhancing medication convenience and drug delivery efficiency

Lipid Matrix

Lipid Matrix This technology stabilizes drugs within a lipid-based matrix,
designed to ensure slow release within the body, thereby
increasing the duration of drug
efficacy and medical compliance.

Double-
Layered Tablet

Biphasic Tablet By creating two distinct layers and
independently designing their release
characteristics or functions, this technology
provides combined therapeutic effects.

ODF

Orodispersible Film This thin film dissolves rapidly when placed on the tongue
without water, allowing for absorption through the oral
mucosa or gastrointestinal tract, thereby improving
portability and ease of administration.

Driven by differentiated technology and innovation,
we are establishing presence in global healthcare market

We build a trusted platform that brings together investors,
partners, customers, and talent, sustainably enhancing
corporate value and brand power.

Drag

Investment in CGB (Cell Gene Bioplatform)
Pangyo Techno Valley 2

CGB is the world’s largest single CGT production facility and serves as a global hub capable of producing CGT, mRNA, viral vectors, and plasmid DNA all under one roof. Furthermore, through collaboration with domestic and international R&D centers and biotech startups, it is evolving into a “CGT Open Innovation Hub.”

Matica Biotechnology Investment
l College Station, Texas

Cha Bio Group has established a global network of five CGT CDMO facilities capable of flexible production ranging from small-scale to large-scale. Through this network, the group supports CGT development companies throughout the entire process—from clinical trial design to product approval—as they aim to enter domestic and global markets.

Group Synergy: Industry, academia, research institutes, hospitals, factories, and government
Ecosystem Development

· Companies: Promoting various industrial projects, including bio-insurance, medical device development, sales of fillers and cosmetics, and animal nutrition and dietary supplement businesses
· Universities: Supporting future talent through joint programs for students
· Hospitals: Providing diverse patient and customer experiences, including clinical research, application of obstetrics
and gynecology products, health screening promotions, and spa programs

Business Diversification
l Total Healthcare Partner

CMG Pharmaceuticals is pursuing stable and sustainable growth by expanding its business into various fields, including not only pharmaceuticals but also obesity treatments, ophthalmology, consumer goods, animal nutrition, and medical devices. This diversification strategy serves as a key driver for strengthening our position as a high-growth company in the future.

R&D Investment
Core Value Connecting the Present and the Future

CMG Pharma is continuously developing platform formulation technologies—such as bilayer tablets, ODF, SMEDDS, and Lipid Matrix—that improve medication convenience and drug delivery efficiency.

Domestic and Global Achievements
Achieving Sustainable Outcomes

2018: Selected as one of the Top 1,000 High-Growth Companies in the Asia-Pacific Region by the Financial Times; Included in the KRX300 Index
2020: Selected as a “Strong Small Enterprise” by the Ministry of Employment and Labor in the Financial Soundness category; Received Grade A in the Technology Evaluation under the Special Provisions for Listed Companies
2021: Technology export of CHC2014 (targeted anticancer drug)
2023: Acquisition of an animal nutrition company (ING MEDIX)
2024: Purchased land for Plant No. 2 (5,863 m²)
2025: Obtained U.S. FDA marketing authorization for ‘MEZOFY,’ an oral film-based schizophrenia treatment

CHA Network

Global Medical Network

Together toward a world-class global biotechnology group

Countries

Medical Centers

1800

Doctors

14000

Members

Cha Hospital History

Cha Bio Group

is building an integrated ecosystem
connecting industry, academia, research institutes, and hospitals.

Through this ecosystem, we create future value in the bio/healthcare
industry by advancing from basic research to candidate discovery,
clinical trials, and commercialization, and reinvesting in research

University

Laboratory

Enterprise

Hospital

Industry-Academia-Research-Hospital-Factory Ecosystem

University Basic Research

Company Commercialization

CDMO Facility

Hospital Clinical Research

Research Institute Translational Research